Assessment of endobronchial ultrasound‐guided bronchoscopy (EBUS) intranodal forceps biopsy added to EBUS 19‐gauge transbronchial needle aspiration: A blinded pathology panel analysis

• Published in: Thoracic cancer 2023-08, Vol.14 (22), p.2149-2157
• Main Authors: Lachkar, Samy, Faur, Quentin, Marguet, Florent, Veresezan, Liana, Bubenheim, Michael, Salaün, Mathieu, Thiberville, Luc, Sabourin, Jean‐Christophe, Guisier, Florian, Piton, Nicolas
• Format: Article
• Language: English
• Subjects: 19‐gauge needle; Biopsy; Bronchoscopy; Cancer; endobronchial ultrasound bronchoscopy; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Granulomas; Humans; intranodal forceps biopsy; Lymph Nodes - pathology; Lymphatic system; Lymphoma; Mediastinum; Metastasis; Neoplasms - pathology; Original; Pathology; Patients; Retrospective Studies; Sarcoidosis; thoracic lymphadenopathy; Tomography; transbronchial needle aspiration; Ultrasonic imaging
• ISSN: 1759-7706; 1759-7714
• DOI: 10.1111/1759-7714.15000

Background Endobronchial ultrasound‐guided (EBUS) transbronchial needle aspiration (TBNA) has significantly improved the diagnostic workup for intrathoracic lymphadenopathies. More recently, EBUS intranodal forceps biopsy (IFB) has been developed in an attempt to maximize diagnostic yield by providing additional tissue. In this study, we aimed to assess the improvement of diagnostic yield with EBUS‐TBNA combined with EBUS‐IFB, compared to EBUS‐TBNA alone. Methods Consecutive patients who had 19‐G EBUS‐TBNA and EBUS‐IFB from August 30, 2018, to September 28, 2021, were included. Four senior pathologists retrospectively analyzed, independently and blindly, first, only the EBUS‐TBNA samples (cell block), then, at least 1 month later, both samples from EBUS‐TBNA and from EBUS‐IFB together. Results Fifty patients were included in the study and 52 lymph nodes were analyzed. Diagnostic yield was 77% (40/52) for EBUS‐TBNA alone and 94% (49/52) when combined with EBUS‐IFB (p = 0.023). Malignancy was diagnosed with EBUS‐TBNA combined with EBUS‐IFB in 25/26 cases (96%), versus 22/26 (85%) with EBUS‐TBNA alone (p = 0.35); and 4/5 (80%) versus 2/5 (40%) for lymphoma specifically. Kappa interobserver agreement was 0.92 for EBUS‐IFB and 0.87 for EBUS‐TBNA alone. Nonmalignant condition was diagnosed with EBUS‐TBNA combined with EBUS‐IFB in 24/26 cases (92%), versus 18/26 (69%) for EBUS‐TBNA alone (p = 0.07). Conclusion The use of EBUS‐IFB combined with 19‐G EBUS‐TBNA improves the mediastinal lymph node diagnostic yield However the benefit appears to be mainly restricted to nonmalignant histology. The use of EBUS‐IFB combined with 19‐G EBUS‐TBNA improves the mediastinal lymph node diagnostic yield. However, the benefit appears to be mainly restricted to nonmalignant histology.